Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation

Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is used as a first-line treatment for patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, the mechanisms underlying its anticancer activity, particularly the subsequent develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishihara, Shigetoshi, Yamaoka, Toshimitsu, Ishikawa, Fumihiro, Ohmori, Tohru, Ando, Koichi, Kusumoto, Sojiro, Kishino, Yasunari, Manabe, Ryo, Hasebe, Yuki, Sagara, Hironori, Yoshida, Hitoshi, Tsurutani, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319811/
https://www.ncbi.nlm.nih.gov/pubmed/35883645
http://dx.doi.org/10.3390/cells11142201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319811/
https://www.ncbi.nlm.nih.gov/pubmed/35883645
http://dx.doi.org/10.3390/cells11142201

Ejemplares similares